Immunohistochemical markers of cell cycle control applied to ovarian and primary peritoneal surface epithelial neoplasms: p21(WAF1/CIP1) predicts survival and good response to platinin-based chemotherapy

Human Pathology

Volumn 30, Issue 6, 1999, Pages 640-647

  Costa, Michael J ^a,b   Hansen, Christian L ^a   Walls, Judy E ^a   Scudder, Sidney A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF LOUISVILLE HOSPITAL   (United States)

Author keywords

Adenocarcinoma; Cancer; Carcinoma; Clear cell; Endometrioid; Immunohistochemistry; Ki 67; Ovary; p53; Serous; Transitional cell mucinous

Indexed keywords

KI 67 ANTIGEN; PLATINUM DERIVATIVE; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CELL CYCLE; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CYSTADENOCARCINOMA; DRUG EFFECT; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; OVARY ADENOCARCINOMA; OVARY CARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; SMALL CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA;

EID: 0033066168     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(99)90088-6     Document Type: Article

References (54)

1. Hand R, Fremgen A, Chmiel JS, et al: Staging procedures, clinical management, and survival outcome for ovarian carcinoma. JAMA 269:1119-1122, 1993
2. Piver MS, Baker TR, Piedmonte M, et al: Epidemiology and etiology of ovarian cancer. Semin Oncol 18:177-185, 1991
3. Hendrickson MR, Longacre TA: Classification of surface epithelial neoplasms of the ovary, in Hendrickson MR (ed): Surface Epithelial Neoplasms of the Ovary. Pathology: State of the Art Reviews, vol 1, no 2. Philadelphia, PA, Hanley & Belfus, 1993, pp 189-254
4. Cramer SF, Roth LM, Ulbright TM, et al: Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. Arch Pathol Lab Med 111:819-829, 1987
5. Shimizu Y, Kamio S, Amada S, et al: Toward the development of a universal grading system for ovarian epithelial carcinoma. Gynecol Oncol 70:2-12, 1998
6. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70:523-526, 1992
7. Marx J: How p53 suppresses cell growth. Science 262:1644-1645, 1993
8. Harris CC: p53: At the crossroads of molecular carcinogenesis and risk assessment. Science 262:1980-1981, 1993
9. El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993
10. El-Deiry WS, Harper JW, O'Connor PM, et al: WAF/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169-1174, 1994
11. Zhang W, Grasso L, McClain CD, et al: p53-independent Induction of WAF/CIP1 in human leukemia cells Is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 55:668-674, 1995
12. Michieli P, Chedid M, Lin D, et al: Induction of WAF/CIP1 by a p53-independent Pathway. Cancer Res 54:3391-3395, 1994
13. Gudas J, Nguyen H, Li T, et al: Effects of cell cycle, wild-type p53 and DNA damage on p21 CIP/Waf1 expression in human breast epithelial cells. Oncogene 11:253-261, 1995
14. Missero C, Calautti E, Eckner R, et al: Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci 92:5451-5455, 1995
15. Chiarugi V, Magnelli L, Cinelli M, et al: Apoptosis and the cell cycle. Cell Mol Biol Res 40:603-612, 1994
16. Gerdes J, Li L, Schlueter C, et al: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138:867-873, 1991
17. Cattoretti G, Becker MH, Key G, et al: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357-363, 1992
18. Barbareschi M, Girlando S, Mauri FM, et al: Quantitative growth fraction evaluation with MIB1 and Ki67 antibodies in breast carcinomas. Am J Clin Pathol 102:171-175, 1994
19. DeLellis RA: Does the evaluation of proliferative activity predict malignancy or prognosis in endocrine tumors. HUM PATHOL 26:131-134, 1995
20. Gallion HH, Pieretti M, DePriest PD, et al: The molecular basis of ovarian cancer. Cancer 76:1992-1997, 1995 (suppl 10)
21. Kupryjanczyk J, Thor A, Beauchamp R, et al: p53 gene mutation and protein accumulation in human ovarian cancer. Proc Natl Acad Sci 90:4961-4965, 1993
22. Kupryjanczyk J, Bell DA, Yandell DW, et al: p53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol 102:671-676, 1994
23. Kupryjanczyk J, Bell DA, Dimeo D, et al: p53 gene analysis of ovarian borderline tumors and stage I carcinomas. HUM PATHOL 26:387-392, 1995
24. Klemi PJ, Takahashi S, Joensuu H, et al: Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gynecol Pathol 13:228-233, 1994
25. Bosari S, Viale G, Radaelli U, et al: p53 accumulation in ovarian carcinomas and its prognostic implications. HUM PATHOL 24:1175-1179, 1993
26. Teneriello MG, Ebina M, Linnoila RI, et al: p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 53:3103-3108, 1993
27. Kohler MF, Kerns BJ, Humphrey PA, et al: Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 81:643-650, 1993
28. Kiyokawa T: Alteration of p53 in ovarian cancer: Its occurrence and maintenance in tumor progression. Int J Gynecol Pathol 13:311-318, 1994
29. Kounelis S, Papadaki H, Kanbour-Shakir A, et al: p53 point mutational damage predicts tumor recurrence in ovarian adenocarcinoma. Mod Pathol 8:92A, 1995
30. Lee JH, Kang YS, Park SY, et al: p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet Cytogenet 85:41-50, 1995
31. Marchenko ND, Moll UM: Nuclear overexpression of p53 protein does not correlate with gene mutation in primary peritoneal carcinoma. HUM PATHOL 28:1002-1006, 1997
32. Righetti SC, Della Torre G, Pilotti S, et al: A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 5:689-693, 1996
33. Buttitta F, Marchetti A, Gadducci A, et al: p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: A molecular and immunohistochemical study. Br J Cancer 75:230-235, 1997
34. Taylor CR, Shi SR, Chaiwun B, et al: Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: Androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen and Ki67 antigen revealed by antigen retrieval techniques. HUM PATHOL 25:263-270, 1994
35. O'Hanlan KA: Principles of surgical management of ovarian carcinomas, in Hendrickson MR (ed): Surface Epithelial Neoplasms of the Ovary. Pathology: State of the Art Reviews, vol 1, no 2. Philadelphia, PA, Hanley & Belfus, 1993, pp 477-489
36. Costa MJ, Hansen C, Dickerman A, et al: The clinicopathologic significance of the transitional cell carcinoma pattern in non-localized ovarian epithelial tumors (stage 2-4). Am J Clin Pathol 109:173-180, 1998
37. Costa MJ, Kenny M, Judd R: Uterine glandular carcinoma: Correlation of histologic classification, immunohistochemistry and grading with origin and outcome. Int J Surg Pathol 1:13-24, 1993
38. Hendrickson MR, Longacre TA, Kempson RL: Clinicopathology of malignant surface epithelial neoplasms of the ovary, in Hendrickson MR (ed): Surface Epithelial Neoplasms of the Ovary. Pathology: State of the Art Reviews, vol 1, no 2. Philadelphia, PA; Hanley & Belfus, 1993, pp 367-410
39. Costa MJ, Walls J, Dickerman A, et al: Cell cycle control of ovarian granulosa cells in tumors and cysts. Int J Surg Pathol 4:61-70, 1996
40. Duncan RC, Knapp RC, Miller MC III: Introductory Biostatistics for the Health Sciences. New York, NY, John Wiley & Sons, 1983
41. Vollmer RT: Multivariate statistical analysis for anatomic pathology. Part II: Failure time analysis. Am J Clin Pathol 106:522-534, 1996
42. Sheikh MS, Li XS, ChenJC, et al: Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: Role of p53-dependent and independent signal transduction pathways. Oncogene 9:3407-3415, 1994
43. Bonfanti M, Taverna S, Salmona M, et al: p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res 57:1442-1446, 1997
44. Steinman R, Hoffman B, Iro A, et al: Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 9:3389-3396, 1994
45. Palazzo JP, Mercer WE, Kovatich AJ, et al: Immunohistochemical localization of p21 WAF1/CIP1 in normal, hyperplastic and neoplastic uterine tissue. HUM PATHOL 27:60-66, 1997
46. Auer G, Einhorn N, Nilsson B, et al: Biological malignancy grading in early-stage ovarian carcinoma. Acta Oncol 35:93-98, 1996 (suppl 8)
47. Wan M, Cofer KF, Dubeau L: WAF1/CIP1 structural abnormalities do not contribute to cell cycle deregulation in ovarian cancer. Br J Cancer 73:1398-1400, 1996
48. Jordan PA, Kerns BM, Pence JC, et al: Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 99:736-740, 1993
49. Kerns BM, Jordan PA, Faerman LL, et al: Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol 101:192-197, 1994
50. Jussila T, Stenbäck F: Cell proliferation markers and growth factors in ovarian cancer. Ann Med 27:87-94, 1995
51. Henricksen R, Strang P, Wilander E, et al: p53 expression in epithelial ovarian neoplasm: Relationship to clinical and pathological parameters, Ki67 expression and flow cytometry. Gynecol Oncol 53:301-306, 1994
52. WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int J Cancer 63:611-615, 1995
53. Gibb RK, Taylor DD, Wan T, et al: Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Gynecol Oncol 65:13-22, 1997
54. Herod JJ, Eliopoulos AG, Warwick J, et al: The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56:2178-2184, 1996